## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PROLLENIUM US INC., Petitioner,

v.

ALLERGAN INDUSTRIE, SAS, Patent Owner.

IPR2019-01505, Patent 8,450,475 B2 IPR2019-01506, Patent 8,357,795 B2 IPR2019-01508, Patent 9,238,013 B2 IPR2019-01509, Patent 9,358,322 B2 IPR2019-01617, Patent 8,822,676 B2 IPR2019-01632, Patent 8,357,795 B2 IPR2020-00084, Patent 9,089,519 B2

## JOINT STIPULATION TO MODIFY DUE DATE 1 IN SCHEDULING ORDER<sup>1</sup>

DOCKE

LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

<sup>&</sup>lt;sup>1</sup> Authorization for the use of a joint caption page was received on April 27, 2020. Neither party opposes the use of a joint caption page. An identical paper has been filed in each case recited in the consolidated caption.

IPR2019-01505, Patent 8,450,475 B2; IPR2019-01506, Patent 8,357,795 B2; IPR2019-01508, Patent 9,238,013 B2; IPR2019-01509, Patent 9,358,322 B2; IPR2019-01617, Patent 8,822,676 B2; IPR2019-01632, Patent 8,357,795 B2; IPR2020-00084, Patent 9,089,519 B2

Prollenium US Inc. ("Petitioner") and Allergan Industrie, SAS ("Patent Owner"), by and through their respective counsel of record, hereby stipulate as follows:

On April 13, 2020, the Scheduling Order in the Inter Partes Review of U.S. Patent No. 8,450,475 (IPR2019-01505), U.S. Patent No. 8,357,795 (IPR2019-01506), U.S. Patent No. 9,238,013 (IPR2019-01508), U.S. Patent No. 9,358,322 (IPR2019-01509), U.S. Patent No. 8,822,676 (IPR2019-01617), U.S. Patent No. 8,357,795 (IPR2019-01632), and U.S. Patent No. 9,089,519 (IPR2020-00084) set forth "due dates for the parties to take action in this trial," and further stated that the "parties may stipulate different dates for DUE DATES 1, 2, 5, and 6, as well as the portion of DUE DATE 3 related to Patent Owner's sur-reply (earlier or later, but no later than DUE DATE 7)." *Id.* at 7.

Patent Owner and Petitioner hereby stipulate to modify DUE DATE 1 as follows:

DUE DATE 1: September 1, 2020

This stipulation does not affect or otherwise modify DUE DATES 2–8 in the Scheduling Order.

IPR2019-01505, Patent 8,450,475 B2; IPR2019-01506, Patent 8,357,795 B2; IPR2019-01508, Patent 9,238,013 B2; IPR2019-01509, Patent 9,358,322 B2; IPR2019-01617, Patent 8,822,676 B2; IPR2019-01632, Patent 8,357,795 B2; IPR2020-00084, Patent 9,089,519 B2

Respectfully Submitted,

Date: August 19, 2020

/Warren J. Thomas/

Warren J. Thomas Reg. No. 70,581 Petitioner, Prollenium US Inc.

Date: August 19, 2020

/Anthony M. Insogna/

Anthony M. Insogna Reg. No. 35,203 Patent Owner, Allergan Industrie, SAS

## **CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served on the counsel for Petitioner a true and correct copy of this Joint Stipulation to Modify Due Date 1 in Scheduling Order by electronic means at the following address of record:

mcc.prollenium.ipr@mcciplaw.com

Dated: August 19, 2020

/Anthony M. Insogna/ Anthony M. Insogna (Reg. No. 35,203) Jones Day 4655 Executive Drive, Suite 1500 San Diego, CA 92121-3134 Tel.: (858) 314-1200 Fax.: (844) 345-3178

Attorney for Patent Owner